Cryologyx Ltd.

Based in Coventry, US, and founded in 2021 by co-founders Tom Congdon and Matt Gibson, Cryologyx Ltd. operates as a biopharmaceutical research-based company developing frozen ready-to-use cells for the medicines discovery, diagnostics, and cell therapy industries. In March 2024, Cryologyx Ltd. raised GBP 0.

50 million in seed funding co-led by Wider Oxford Technology Angel Network and Oxford Technology Management.   Cryologyx Ltd. specializes in the development of assay-ready cryopreserved cells, eliminating the need for routine cell culture and simplifying cell-based assays. Its technology supports scientists and medical research professionals to reduce post-thaw cell damage, enabling direct use from the freezer and improving traditional cell culture methods.

The company offers assay-ready cryopreserved cells under different product lines, including Tox Ready, Plaque Ready, and Custom Ready models. These cells are plated and cryopreserved into various plate formats, optimized for immediate use in a wide range of experiments, including drug screening and infectivity assays.   The company generates revenue by selling their products, that includes ToxReady HepG2 Well Plate, ToxReady A549 Well Plate, Plaque Ready Vero Well Plate, and Plaque Ready BHK-21 Well Plate from their e-commerce website for GBP 250.   The company plans to use the funding from March 2024 to support commercialization of the company’s innovative cryopreserved cell technology, scale up production of its assay-ready cells and expand its reach in the UK and Europe.